Keyphrases
Biological Markers
100%
Non-muscle Invasive Bladder Cancer (NMIBC)
100%
Simulation Study
100%
Bacillus Calmette-Guérin
100%
Biological Simulation
100%
Mathematical Model
16%
Immunohistochemistry
16%
Biochemical Markers
16%
Ki-67
16%
Patient-specific
16%
Adjuvant Therapy
16%
Molecular Biology
16%
Immune Cells
16%
Genetic Polymorphism
16%
Interleukin-2
16%
MicroRNA
16%
Signaling Molecules
16%
Epigenetics
16%
Prevent Recurrence
16%
Molecular Markers
16%
Surface Proteins
16%
Interleukin-8
16%
Cytokine Signaling
16%
Tumor-associated Macrophages
16%
Immunological Response
16%
Bacillus Calmette-Guérin Instillation
16%
Mathematical Methods
16%
Rational Selection
16%
Human Leukocyte Antigen Class I
16%
Cellular Biology
16%
Bacillus Calmette-Guérin Vaccine
16%
CK20
16%
Tumor Response
16%
Cell Markers
16%
Clinical Input
16%
IL-6/IL-10
16%
Medicine and Dentistry
Biological Marker
100%
Mycobacterium Bovis BCG
100%
Non Muscle Invasive Treatment of Bladder Cancer
100%
Neoplasm
33%
Malignant Neoplasm
16%
Immunohistochemistry
16%
Recurrent Disease
16%
Immunocompetent Cell
16%
microRNA
16%
Interleukin-6
16%
Cytokine Signaling
16%
Biochemical Marker
16%
Molecular Marker
16%
Adjuvant Therapy
16%
Macrophage
16%
Genetic Polymorphism
16%
BCG Vaccine
16%
Signaling Protein
16%
Cell Marker
16%
Human Leukocyte Antigen
16%
Epigenomics
16%
Cell Surface Protein
16%
Bladder Carcinoma
16%
Pharmacology, Toxicology and Pharmaceutical Science
Biological Marker
100%
Non Muscle Invasive Bladder Cancer
100%
Mycobacterium Bovis BCG
100%
Neoplasm
33%
Cytokine
16%
Malignant Neoplasm
16%
Biochemical Marker
16%
Recurrent Disease
16%
microRNA
16%
Bladder Carcinoma
16%
BCG Vaccine
16%
Cell Surface Protein
16%
Cell Marker
16%
Leukocyte Antigen
16%
Molecular Marker
16%
Immunology and Microbiology
Mycobacterium Bovis BCG
100%
Interleukin-6
16%
Genetic Polymorphism
16%
Immunocompetent Cell
16%
Epigenetics
16%
Cell Surface
16%
Cytokine Signaling
16%
Genetic Marker
16%
Tumor-Associated Macrophage
16%
BCG Vaccine
16%
Human Leukocyte Antigen
16%